AZTA earnings

FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 millionFY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growthFY'26 Adjusted EBITDA margin is now expected to range from down approximately 125 basis points to flat, compared to prior expectations of approximately 300 basis points of expansionLong-range plan timing updated to 2029 versus 2028 before in connection with revised 2026 guidance. Market opportunities, strategic priorities, and value creation framework remain intact.BURLINGTON, Mass., May 5, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financi

BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 7, 2026.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactf

BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsBURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2025 2024(1) Change 2025 2024(1) Change Revenue

BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Friday, November 21, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 22, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solut

BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling imp

BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnnounces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Fiscal Year 2024 Highlights: Q4'24 revenue growth o

BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 13, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solu

BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C

BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 7, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling im

BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2024. Quarter Ended Dollars in millions, except per share data March 31,  December 31,  March 31,  Change 2024 2023 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 159 $ 154 $ 148 3 % 7 %    Organic growth 7 % Sample Management Solutions $ 74 $ 79 $ 71 (6) % 4 % Multiomics $ 62 $ 63 $ 62 (1) % (0) % B Medical Systems $ 23 $ 13 $ 15 81 % 51 % Diluted EPS Continuing Operations $ (2.47) $ (0.28) $ (0.03) nm nm Diluted EPS Total $ (2.47) $ (0.28) $ (0.07) nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.05 $ 0.02 $ (0.06) 102 % 184 %

BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2024 earnings which ended on March 31, 2024, on Wednesday, May 8, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time. Conference call participants may access the call using the following online registration link. Registrants will receive a confirmation containing dial in details and a unique conference call code for entry. Analysts, investors, and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com

BURLINGTON, Mass., Feb. 7, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2023. Quarter Ended Dollars in millions, except per share data December 31,  September 30,  December 31,  Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 154 $ 172 $ 178 (10) % (13) %    Organic growth (15) % Sample Management Solutions $ 79 $ 82 $ 75 (3) % 5 % Multiomics $ 63 $ 61 $ 61 3 % 3 % B Medical Systems $ 13 $ 29 $ 42 (57) % (70) % Diluted EPS Continuing Operations $ (0.28) $ 0.05 $ (0.15) (690) % (79) % Diluted EPS Total $ (0.28) $ 0.06 $ (0.15) (591) % (79) % Non-GAAP Diluted EPS Continuing Operations $

BURLINGTON, Mass., Jan. 25, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2024 earnings which ended on December 31, 2023, on Wednesday, February 7, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 7, 2024, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-5171 for domestic callers and +1- 212-231-2906 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET

Q4'23 reported revenue growth of 25% year over year and 2% on an organic basisFY'23 reported revenue growth of 20% and down 1% on an organic basisQ4'23 generated positive free cash flow for the second consecutive quarterFiscal 2024 organic revenue growth expected to be 5-8% Committing to an additional $500 million in share repurchases in Fiscal 2024 BURLINGTON, Mass., Nov. 13, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2023. Quarter Ended Year Ended Dollars in millions, except per share data September 30,  September 30,  September 30,  September 30,  2023 2022 Change 2023 2022 Change Revenue fro

BURLINGTON, Mass., Aug. 8, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2023. Quarter Ended Dollars in millions, except per share data June 30,  March 31, June 30,  Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 166 $ 148 $ 133 12 % 25 %    Organic growth 2 % Life Sciences Products $ 75 $ 59 $ 47 27 % 57 % Life Sciences Services $ 91 $ 90 $ 85 2 % 7 % Diluted EPS Continuing Operations $ (0.04) $ (0.03) $ (0.09) (35) % 59 % Diluted EPS Total $ (0.02) $ (0.07) $ (0.13) 67 % 82 % Non-GAAP Diluted EPS Continuing Operations $ 0.13 $ (0.06) $ 0.12 nm 12 % Adjusted EBITDA Continuing Operations $

BURLINGTON, Mass., Aug. 3, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2023 earnings which ended on June 30, 2023 on Tuesday August 8, 2023 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday August 8, 2023, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-954-0585 for domestic callers and +1-212-231-2927 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 9, 2023

BURLINGTON, Mass., May 9, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2023. Quarter Ended Dollars in millions, except per share data March 31,  December 31,  March 31,  Change 2023 2022 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 178 $ 146 (17) % 2 %    Organic growth ex-COVID impacts (2) % Life Sciences Products $ 59 $ 90 $ 54 (34) % 10 % Life Sciences Services $ 90 $ 89 $ 92 1 % (3) % Diluted EPS Continuing Operations $ (0.03) $ (0.15) $ (0.02) nm nm Diluted EPS Total $ (0.07) $ (0.15) $ 28.28 nm nm Non-GAAP Diluted EPS Continuing Operations $ (0.06) $ 0.12 $ 0.12 nm nm Adjusted EBITDA Conti

BURLINGTON, Mass., May 3, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2023 earnings which ended on March 31, 2023 on Tuesday, May 9, 2023 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday May 9, 2023, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-9761 for domestic callers and +1-212-231-2919 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 10, 2023. Abou

Reported Q1'23 Revenue of $178 Million and Growth of 28% Year-Over-YearDelivered Organic Growth Excluding COVID of 7%Reducing Cost Structure to Deliver Two Points of Margin Enhancement in 2nd Half FY23BURLINGTON, Mass., Feb. 8, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2022. Quarter Ended Dollars in millions, except per share data December 31,  September 30,  December 31,  Change 2022 2022 2021 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 178 $ 138 $ 140 30 % 28 %    Organic growth ex-COVID impacts 7 % Life Sciences Products $ 90 $ 48 $ 50 85 % 80 % Life Sciences Services $ 89 $ 89 $ 90 (1) % (1) % Di

BURLINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2023 earnings which ended on December 31, 2022 on Wednesday, February 8, 2023 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 8, 2023, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-908-8386 for domestic callers and +1-212-231-2924 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on

  Delivered on Expected Q4'22 Revenue of $138 millionStrong Double-Digit Organic Growth Excluding COVID for Q4 and Full Fiscal Year Plan to Repurchase at Least $1 Billion of Common Stock Over the Coming Year, Including $500 Million Accelerated Share Repurchase Program30% Total Revenue Growth Expected in Fiscal 2023CHELMSFORD, Mass., Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2022. Quarter Ended Year Ended Dollars in millions, except per share data September 30,  September 30,  September 30,  September 30,  2022 2021 Change 2022 2021 Change Revenue from Continuing Operations $ 138 $ 137

CHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time.  To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events.  A replay will be available beginning at 8:3

CHELMSFORD, Mass., Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2022. Quarter Ended Dollars in millions, except per share data June 30,  March 31,  June 30,  Change 2022 2022 2021 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 133 $ 146 $ 129 (9) % 3 % Life Sciences Products $ 47 $ 54 $ 49 (12) % (3) % Life Sciences Services $ 85 $ 92 $ 80 (7) % 6 % Diluted EPS Continuing Operations $ (0.09) $ (0.02) $ (0.02) nm nm Diluted EPS Total $ (0.13) $ 28.28 $ 0.53 nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.12 $ 0.12 $ 0.10 0 % 14 % Adjusted EBITDA Continuing Operations $ 14 $ 19 $ 19 (29) % (26) % M

Enhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in O

CHELMSFORD, Mass., July 13, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared to the third quarter of fiscal 2021. Year-over-year organic growth is expected to be 6%, after adjusting for approximately 3 percentage points of currency impact. GAAP diluted EPS from continuing operations is expected to be in the range of ($0.13) to ($0.08), driven lower than expected primarily due to income taxes. Non-GAAP diluted EPS is expected to be in the range of $0.08 to $0.12. Revenue for the Services segment is expected to be approximatel

Robust customer demand bolstered by operational execution drives strong second quarter results CHELMSFORD, Mass., May 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022. Summary of Preliminary Results On February 1, 2022, the Company completed the sale of its Semiconductor Automation business.  The related gain on the sale and the results of the Semiconductor Automation business are treated as discontinued operations and reflected in total diluted EPS.  Due to the complexities of the financial carve-out of the business from the Company's financial results, the Company expects it will require additional

CHELMSFORD, Mass., April 28, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which ended on March 31, 2022 from Tuesday, May 3, 2022 to Monday, May 9, 2022 after the market closes. The change is due to a delay in completing the quarter-end closing process related to the sale of the Semiconductor Automation business, which closed on February 1, 2022. Azenta currently expects second quarter revenue and non-GAAP EPS to be within the previously issued guidance range. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, May 9, 2022

CHELMSFORD, Mass., April 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal 2022 second quarter earnings which ended on March 31, 2022 on Tuesday, May 3, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, May 3, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-6194 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 4, 2022. Ab

CHELMSFORD, Mass., Feb. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fiscal quarter ended December 31, 2021. Summary of Results Results of continuing operations reflect the Life Sciences business. Due to the agreement reached in the fourth fiscal quarter of 2021 to divest the semiconductor automation business, the results of the semiconductor automation business are treated as discontinued operations and reflected in total diluted EPS. Quarter Ended Dollars in millions, except per share data December 31,  September 30, December 31,  Change 2021 2021 2020 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 140 $ 137 $ 118 2 % 18 % Life Sci

CHELMSFORD, Mass, Jan. 24, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021 on Tuesday, February 8, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, February 8, 2022 at 4:30 p.m. Eastern Time.  To participate in the conference call, please dial 800-584-1012 for domestic callers and +1-212-231-2907 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events.  A replay will be available beginning at 8:30 a.m.